GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocolInitiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant fundingPhase 1 dose escalation basket trial with GTB-5550 in solid tumor patients…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.